Skip to main content
. 2020 Jun 23;7(7):ofaa246. doi: 10.1093/ofid/ofaa246

Figure 1.

Figure 1.

(a) Incidence of primary Pseudomonas aeruginosa (PSA) infections in a cohort of 1314 allogeneic hematopoietic cell transplant (HCT) recipients. (b) Ninety-day incidence of recurrent PSA infections among 43 allogeneic-HCT recipients after completion of treatment of their primary PSA infection. (c) Ninety-day incidence of recurrent PSA infections based on treatment duration of primary infection for <14 vs ≥14 days. (d) Ninety-day incidence of recurrent PSA infections based on treatment duration of primary infection for <21 vs ≥21. (e) Ninety-day incidence of recurrent PSA infections based on primary PSA infection type (bloodstream infection [BSI] only vs lower respiratory tract infection [LRTI] with and without BSI) and treatment duration of primary infection for <14 vs ≥14 days. (f) Ninety-day incidence of recurrent PSA infections based on primary PSA infection type (BSI only vs LRTI with and without BSI) and treatment duration of primary infection for <21 vs ≥21 days.